PD-1/PD-L1

Nov 05, 2026

After KEYTRUDA: How PD-1 and PD-L1 Inhibitors Are Being Redesigned for a Post-Patent Era

Sep 23, 2024

Roche’s TECENTRIQ HYBREZA: Setting New Standards as the First Subcutaneous Anti-PD-(L)1 Drug

Jun 14, 2024

OPDIVO vs. KEYTRUDA: The Battle for Japan’s PD-1 Inhibitor Market Dominance

Jun 03, 2024

Rapid Global Expansion of Chinese PD-1/PD-L1 Key Players

Newsletter/Whitepaper